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Twenty-one patients with chronic stable angina were
treated with the calcium antagonist diltiazem. Dose ti-
tration studies involving 180, 270 and 360 mg/day were
conducted using a blinded objective protocol. Improve-
ment in exercise tolerance was observed at all dose levels,
but the best reduction of anginal attacks and glyceryl
trinitrate consumption, enhancement of exercise capac-
ity and improvement of objective ischemic variables were
observed with the 360 mg/day dose. The mean exercise
time to produce grade II angina on treadmill walking
increased from 5.6 :±: 0.7 minutes on placebo to 7.9 :±:
0.8 minutes on diltiazem 180 mg/day (probability [p] <
Diltiazem, a calcium antagonist drug developed in Japan
and newly released in the United States and United King-
dom, has powerful coronary vasodilating properties and has
been used successfully in Prinzmetal's variant angina (l,2).
Some reports have suggested that it may also be effective
in chronic stable angina (3-6). We conducted a controlled
study to determine the efficacy of three dose levels of dil-
tiazem as measured by a number of objective variables using
exercise testing and 24 hour ambulatory electrocardio-
graphic monitoring in patients with chronic stable angina
due to obstructive coronary artery disease that had not re-
sponded to conventional therapy.
Methods
Patients. Twenty-one patients (19 men and 2 women) aged 48
to 68 years entered the study. The inclusion and exclusion criteria
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0.001), 8.0 :±: 0.8 minutes on 270 mg/day and 9.5 :±: 0.9
minutes on 360 mg/day (p < 0.001 as compared with
270 mg/day). One patient was withdrawn at the 360 mg/
day dosage because of pedal edema. The 24 hour Holter
monitoring data confirmed the findings on exercise test-
ing, and left ventricular function was not altered with
any dose level. Diltiazem in doses ranging from 180 to
360 mg/day is another powerful antianginal agent in the
calcium antagonist group producing excellent therapeu-
tic benefit in chronic stable angina with no adverse effects
on left ventricular function.
have been reported previously (7,8). The patient data and the drugs
previously administered are shown in Table 1. The initial assess-
ment consisted of an exercise test performed at least 2 weeks after
gradual and complete withdrawal of all therapy.
Trial design. The beginning of the trial consisted of a 2 week
single blind placebo run-in phase. The patients then entered a
double blind randomized crossover phase of diltiazem therapy.
Each phase of the crossover consisted of 2 weeks of administration
of the drug, 60 or 90 mg three times a day. At the end of the
crossover phase, the patients entered a final phase of 2 weeks with
120 mg of diltiazem given three times a day in a single blind
fashion. During the double blind phase neither the investigator nor
the patient knew the dose of the drug and during the single blind
phase the patients were also unaware of the nature of their med-
ication. All tablets were packed in identical "blister" packs uti-
lizing the double dummy technique.
Drug assessment. The effect of the placebo and diltiazem was
assessed subjectively and objectively. The patients maintained a
detailed diary of the frequency of their anginal attacks and the
number of sublingual glyceryl trinitrate tablets consumed. They
were clearly instructed as to the importance of keeping an accurate
diary of anginal attacks and side effects. Sublingual nitrates were
not allowed prophylactically.
Treadmill Exercise Testing
Objective evaluation was achieved by performing serial max-
imal treadmill exercise tests before entry into the trial and after
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Table 1. Patient Data and Exercise Time
Previous Treatment
Exercise Time (min)
Case Age (yr) & Sex and Daily Dosage A B C D E
1 61M Verapamil, 360 mg 6.2 6.0 7.1 8.4 9.2*
2 68M Veraparml, 360 mg + m1.7 3.4 2.4 2.0 5.0 5.0
propranolol, 60 mg
3 62M Propranolol, 480 mg + 3.6 2.0 2.0 2.5 2.7
isosorbide, 80 mg
4 53M Propranolol, 240 mg 3.2 3.5 4.0 4.6 6.0
5 66M Oxprenolol, 320 mg 3.2 2.2 1.7 4.2 5.5
6 68M Propranolol, 240 mg 7.1 5.0 5.7 8.1 10.2*
7 60F Verapamil, 360 mg + 4.6 1.8 2.0 6.0 6.9
metoprolol, 100 mg
8 65M Verapamil, 360 mg 10.1 6.3 5.8 9.0 11.0
9 48M Molsidornme, 60 mg 9.6 8.6 9.3 13.0 14.1*
10 52M Metoprolol, 400 mg 10.1 9.4 9.4 10.4 110
II 54M Verapamil, 360 mg 6.0 4.2 4.3 6.0 8.0
12 48M Propranolol, 240 mg 9.8 8.7 9.2 14.5* 16.3*
13 63M Oxprenolol, 320 mg 2.8 2.9 35 4.5 5.5
14 66F Propranolol, 120 mg 5.0 4.0 4.3 5.2 7.7
15 68M Verapamil, 360 mg + 5.8 7.6 7.0 9.4 13.2*
isosorbide, 80 mg
16 67M Verapamil, 360 mg 8.0 3.2 4.0 8.1* 9.4*
17 62M Nifedipine, 30 mg 7.1 7.1 6.9 8.2 11.0*
18 68M Nifedipine, 30 mg +- 2.8 2.5 2.7 6.6 9.0
atenolol, 100 mg
19 68M Disopyramide, 300 mg + 15.0 12.1 132 15.8 18.8*
mfedipine, 30 mg
20 51M Propranolol, 120 mg 5.0 6.2 72 9.2 Withdrawn
21 57M Propranolol, 240 mg 3.1 4.6 5.1 8.2 10.3*
Mean 6.3 5.3 5.5 7.9 9.5
±SEM 0.3 0.6 0.7 0.8 0.9
*Free of angina on maximal exercise.
A = e.xerc!se time (inminutes) onprevious treatment. B = exercise time on notreatment. C = exercise time onplacebo: 0 = exercise time ondiltiazem. 180 mg/day:
E = exercise time on drltiazem, 360 mg/day: SEM = standard error of the mean
administration of all medication, active or inactive, at 2 week
intervals. All exercise tests were performed in the morning at least
2 hours after a light breakfast and 120 to 180 minutes after the
administration of the last dose of diltiazem. The patients arrived
at the exercise laboratory at least 30 minutes before the test and
rested comfortably. They were instructed not to smoke or to take
glyceryl trinitrate tablets on the morning of the test.
Exercise protocol. The exercise test was performed with use
of a microcomputer-based system (Marquette Computer Assisted
System for Exercise) linked to a Quinton treadmill (Fig. I). The
treadmill protocol is shown in Figure 2. The speed and gradient
were automatically controlled by the computer and the test was
timed with a built-in digital clock to an accuracy of 0.1 minute.
All tests were continued until the patient developed the following
symptoms: angina (grade II), pain in the legs, severe breathlessness
or fatigue. Standard safety procedures and legal requirements as
recommended for adult exercise testing laboratories by the Amet-
ican Heart Association (9) were followed. Two bipolar electro-
cardiographic leads were continuously monitored at rest, during
exercise and for a minimum of 5 minutes after exercise. Systolic
blood pressure was monitored every 3 minutes with a mercury
sphygmomanometer.
Recording and measurements. The electrocardiographic leads
monitored were CM 5 (manubrium sterni negative and LV 5 ex-
ploring electrode) and CC 5 (RV6 negative and LV 5 exploring elec-
trode); a lead showing large P waves was used to monitor ar-
rhythmias. The test electrocardiogram was passed to the computer
to form the rest template. The computer calculated ST segment
depression at the J point in reference to the most horizontal part
of the PR segment and expressed it in multiples of 0.1 mm (Fig.
3). The averaged ST segment depression, heart rate and ectopic
beat count were printed automatically for both leads every minute
during and after exercise. During the entire test, the electrocar-
diogram was recorded continuously as 25 beat averages at a paper
speed of I mm/s with ectopic complexes being recorded in real
time. At the end of the test, the computer printed out the exercise
time, maximal heart rate, maximal ST depression and ectopic
complex count. A continuous trend graph of heart rate and ST
depression in all three leads was also obtained. The measurement
circuits of the computer were calibrated daily (Fig. 3).
Data collection. From the continuous printouts the following
data were available:
I. Rest heart rate and ST segment levels.
2. Exercise heart rate, ST levels and ectopic complex count every
minute during and after exercise.
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Figure 1. Exercise testing flow chart. BP =
blood pressure; ECG = electrocardiogram.
3. Maximal heart rate,
4. Maximal ST depression (in leads CMs and CCs).
5, Exercise time,
The following variables could then be calculated:
1. Heart rate gain = maximal heart rate minus heart rate at rest.
2, Heart rate recovery in 5 minutes = maximal heart rate minus
heart rate 5 minutes after recovery.
3. Heart rate at same exercise time = heart rate after treatment
at the same exercise time at which the patient experienced
angina during placebo therapy,
4, I mm time = time taken to develop I mm ST depression
relative to the level at rest.
5. 2 mm time = time taken to develop 2 mm ST depression
relative to the level at rest.
6. Corrected maximal ST depression (MST) = ST depression
immediately at the point of termination of exercise, corrected
for values at rest.
7. Maximal ST depression/exercise time.
8. ST recovery in 5 minutes after exercise.
20
9, Rate-pressure product = systolic blood pressure multiplied
by heart rate and divided by 100.
10. Work done = distance walked in kilometers multiplied by
the sine angle of treadmill in degrees.
Ambulatory Electrocardiographic Monitoring
Twenty-four hour ambulatory Holter electrocardiographic mon-
itoring was performed using a frequency-modulated tape recorder
(Oxford Medilog Mark 2) (Fig, 4) (10, II) with a frequency re-
sponse of 0.05 to 100 Hz for the recorder and 0.1 to 100 Hz for
the entire system,
The recorder. The tape recorder is compact (15,2 ern x 9, I
cm x 2.8 em) and contoured; it weighs only 390 g. It uses an
ordinary C-120 magnetic cassette tape to record four channels of
information for 24 continuous hours. The information recorded
consists of two channels of electrocardiogram, clock time and
flutter compensation signals, The recorder is operated by an al-
kaline battery and is worn by the patient with little discomfort.
The electrocardiogram is acquired by a specially formulated elec-
20
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Figure 2. Schematic diagram of the exercise protocol used
In all studies The stages last 3 minutes each At stage I, the
speed IS 2 mph with no gradient. At stage II, the speed IS
increased by the computer to 3 mph and the gradient to 4%.
The gradient is increased by 4% every 3 minutes and the
speed held constant at 3 mph. In stage VII, the speed is
increased to 4.5 mph with the gradient ~t 20%.
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Figure 3. Schematic diagram of ST segment analysis performed by Mar-
quetteCASE system.
trode with stable characteristics and an aggressive adhesive (NDM
diaphoretic electrodes).
Proper electrodeapplication is an absolute requirement to achieve
good ST segment signals free from artifact and baseline shift. The
chosen sites were over bony surfaces away from major muscle
masses. The hair was shaved if necessary and the skin cleansed
with isopropyl alcohol. The prepared site was outlined by a felt
marker and the skin lightly abrased with a battery-operated dental
burr to remove the epidermis. The electrodes were then applied
and the cables connected. The electrodes and cable junctions were
attached to the skin with adhesive plaster and the recorder fitted
into a pouch worn on the front of the chest. The recorder and
cables were snugly fixed to the chest with an elastic vest to elim-
inate movement.
Tape analysis (Fig. 5). Tape analysis is performed in three
stages:
1. Visual inspection. The tape signal was recalled using an
Oxford PB4 replay unit and displayed on a Reynolds Medical
Pathfinder (Reynolds Medical). The quality of the tape recording
and any gross abnormalities were appraised by the operator during
this phase.
2. Analog write-out. The tape was removed and, if suitable
for analysis, played back into the Reynolds Medical Pathfinder
Rise
Run
Slope (mv I sec)
J poi nt depression
(Rise)
I
I
I
I
I
+ i ~RR interval
Sr-sT;pe
(Run)
using the trend system to identify the ST segment. The Reynolds
Medical trend system generates two bright spots, one of which
was placed manually on the PR isoelectric line and the other at
the J point. The electrocardiogram was then displayed continuously
and the system measured the voltage difference between these two
points averaged for 10 beats with automatic rejection of artifact
and ectopic beats. The system performed simultaneous RR interval
analysis and the ST segment and heart rate changes were registered
graphically as an analog trend chart using two channels of a linear
recorder; the analyzer related the changes to the standard calibra-
tion signals. This presentation permitted rapid visual assessment
of patterns of ST depression or elevation that could be related to
time events from a diary card and was amenable to semiquantitative
analysis.
3. Quantitative analysis. The digital system was designed to
work with the Reynolds Medical ST trend system. An interfacing
module was built to enable the calibrated heart rate and ST segment
change from the trend system to be transferred into a commercially
available minicomputer (MINC PDP 11/23) with twin 8 inch (20.3
ern) floppy disc drives. The computer was programmed to give an
on-line data analysis option and an off-line data retrieval and anal-
ysis option.
Computer program. The initial program "menu" consisted
of patient identification, recorder identification, the electrocardio-
graphic leads recorded, time of starting the recording, times of
symptoms and the date of the recording. The zero reference point
was transferred to the computer together with the I mV square
wave calibration pulses recorded on each tape. The computer was
programmed to reject noisy or distorted calibration signals and
produce an average of 15 pulses. If a satisfactory calibration signal
was not obtained, a standard internal calibration could be utilized.
The tape deck was then started and the signals passed continuously
into the computer. The computer program also contained noise
rejection and artifact-sensing circuitry. Once the tape was run
through, the data were transferred to a floppy diskette for future
analysis and retrieval. The entire procedure of digitizing took about
I hour per tape for two electrocardiographic channels.
The data stored on each floppy diskette were mean heart rate,
maximal heart rate, minimal heart rate, mean ST depression, max-
Glock time
Figure 4. Flow chart of hardware configuration
for ambulatory electrocardiographic (ECG) mon-
itoring analysis. AID = analog to digital: FM =
frequency-modulated; RME = Reynolds Medical.
Tape replay -.
Oxford PB4 EGG RME Normal ST analysis
Digital
replay deck -+ interface with
(FM) clocktime pathfinder beats module AID converter
Normal I 1 . ST 1Heart
abnormal beats counting segment rate
Event module Watanabe 4 Microcomputer
and ectopic linear with floppy disc
counter recorder storage
t
Texas SR 7001
QUME 5 printer
t
Statistics
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imal ST depression and minimal ST depression for every minute.
Software programming enabled the operator to recall any period
either as minute values or as averaged values. The operator could
preset variable normal limits, and the total time duration and the
mean ST change were also available to allow calculation of the
area of ST depression in a given time. In addition, the off limit
ST values or heart rate values could be deleted or included and
identified by distinct markers. With this program, digital anaylsis
could be performed in less than 1 minute per sequence after the
data had been stored in the diskettes. A graphic plotting program
enabled a trend to be generated from digital values within 30
seconds.
Left Ventricular Function
Left ventricular function was measured noninvasively by sys-
tolic time intervals measured in the supine posture. The first de-
rivative of the electrical impedance cardiogram (dZ/dt) (12) was
used as the central arterial pulse waveform. The impedance car-
diogram and the electrocardiogram were simultaneously fed into
a minicomputer that calculated the systolic time intervals (Fig. 6)
(13). We used 100 beat averaging during quiet supine rest with
additional averaging of the first 20 beats with the breath held in
expiration. All studies were performed in the morning after 20
minutes of supine rest. The data obtained included heart rate, pre-
ejection period (PEP), left ventricular ejection time (LVET), PEPI
LVET ratio, RZ interval and (dZ/dt)/RZ ratio (14-18).
Clinical assessment and plasma drug levels. During each
visit, the patients were questioned in detail from a standard ques-
tionnaire to elicit side effects and examined for pedal edema, raised
jugular venous pressure and basal crepitations. Routine biochem-
ical investigations were performed at each visit. Plasma diltiazem
levels were estimated at each period by gas liquid chromatography
(19) and blood was collected 120 to 150 minutes after the last dose
of the drug. The serum diltiazem levels and tablet counting were
used to test compliance. The compliance in taking the drugs ap-
peared to be exceptionally good because of the low side effects
profile of the drug. The side effects were carefully monitored by
a combination of diaries kept by the patient and inquiries from the
standard questionnaire at the time of each clinic visit. Statistical
analysis was performed using Student's paired t test. Informed
consent was obtained from each patient and the protocol was ap-
proved by the Hospital Ethical Committee.
Results
The previous drug treatment consisted of beta-adrenergic
receptor blocking drugs in 10 patients, calcium ion antag-
onist drugs either alone or in combination in 10 patients and
molsidornine in 1 patient (Table 1). All patients entered the
diltiazem trial after gradual and complete withdrawal of all
treatment except sublingual glyceryl trinitrate. Twenty of
the 21 patients completed all four phases of the study and
1 was withdrawn during the 120 mg three times a day phase
because of pedal edema.
Exercise tolerance (Fig. 7). All 21 patients developed
classic angina during treadmill exercise at the end of the
placebo phase. Their exercise tolerance ranged from 1.7 to
13.2 minutes on the standard exercise protocol. The mean
exercise time (± standard error of the mean) to produce
angina during placebo administration was 5.5 ± 0.7 min-
utes. Five patients developed angina within 3 minutes of
walking at 2 miles per hour with no gradient (stage 1), eight
within 6 minutes (stage ll), four in stage Ill, three in stage
IV and one in stage V.
Treatment with diltiazem, 60 mg three times a day, ren-
dered 2 of 21 patients angina-free on treadmill exercise and
increased exercise tolerance to a mean of 7.9 ± 0.8 minutes
(range 2.5 to 15.8) (p < 0.001). Only one patient continued
to develop angina in stage 1. The dose of 90 mg three times
a day abolished exercise angina in four patients but the mean
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Figure 6. Flow chart of on-line computer anal-
ysis of systolic time intervals. dZ/dt = derivative
of the electrical Impedance cardiogram; ECG =
electrocardiogram.
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Figure 7. Individual exercise times of 21 patients receiving 120 mg three
times a day. The mean values are shown on top.
exercise time of 8.0 ± 0.8 minutes was not significantly
different from that with the 60 mg three times a day dose.
The dose of 120 mg three times a day produced a marked
improvement in exercise tolerance as compared with pla-
cebo and other drug dose levels. Eight patients became
angina-free during exercise and the mean exercise time im-
proved to 9.8 ± 0.8 minutes (p < 0.001 versus placebo
and lower doses).
The incidence of anginal attacks was 26 ± 8 episodes
per week on placebo. This decreased to 23 ± 10 episodes
per week on diltiazem, 60 mg three times a day, and to 15
± 5 episodes on 90 mg three times a day. A further re-
duction (p < 0.01) to 8 ± 4 episodes occurred on the 120
mg three times a day schedule. A mean of 33 ± 10 glyceryl
trinitrate tablets was consumed during the placebo period,
decreasing to 21.4 ± 10 on 60 mg three times a day, 12
± 3 on 90 mg three times a day and 9 ± 4 on 120 mg
three times a day, respectively. The values obtained with
diltiazem, 120 mg three times a day, were significantly
better than those with placebo (p < 0.01).
ST segment changes (Table 2). The mean exercise time
required to develop I mm ST depression from the level at
rest was 3.4 ± 0.4 minutes (range 1.0 to 7.0) on placebo.
With the 60 mg three times a day diltiazem dose, this im-
proved to 4.8 ± 0.5 minutes (p < 0.001). There was no
further change at the 90 mg three times a day dose (5.0 ±
0.6 minutes) but there was a significant increase at the 120
mg three times a day dose. Similar changes were seen in
the 2 mm ST depression time. The peak ST segment change
on termination of exercise increased from - 1.9 ± 0.1 mm
on placebo to - 2.2 ± 0.2 mm on the 120 mg three times
a day dose (p = NS). There was a progressive decrease in
the maximal ST depression/exercise time with each increase
in dose and, with the exception of the difference between
the values at the 90 and 120 mg three times a day dose
levels, these differences were statistically significant. The
ST segment recovery remained unaltered at all dose levels
despite a marked improvement in exercise tolerance .
Heart rate (Table 2). The mean heart rate at rest was
75 ± 3 beats/min with placebo. This decreased to 65 ± 2
beats/min on 60 and 90 mg three times a day and to 64
± 2 beats/min on 120 mg three times a day. The maximal
heart rate was 123 ± 3 beats/min on placebo and remained
unchanged with diltiazem treatment. The heart rate gain
showed a slight but insignificant increase. The heart rate
gain per minute of exercise was 8.8 beats/min on placebo.
This decreased to 6.8 beats/min of exercise on the 60 mg
three times a day dose and to 5.9 beats/min of exercise on
the 90 mg three times a day dose. No further change was
observed with the 120 mg dose. There was also no change
in the heart rate recovery in the postexercise period, and
the peak rate-pressure product was not altered by treatment.
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Table 2. Exercise Test Values in 21 Patients During Placebo and 180,270 and 360 mg/day Diltiazem Therapy
Diltiazem
Variable Placebo 180 mg/day 270 mg/day 360 mg/day pi p2 p3 p4
Ex. time (min) 5.5±0.7 7.9±0.8 8.0±0.8 9.5±0.9 <0.001 <0.001 NS <0.001
Heart rate (beats/min)
Rest 75.0±3 65.0±2 65.0±2 64.0±2 <0.001 <0.001 NS NS
Maximal 123.0±3 120.0±4 118.0±3 l20.0±4 NS NS NS NS
Gam 49.0±3 54.0±4 53.0±3 56.0±4 NS NS NS NS
Recovery 46.0±2 47.0±3 46.0±2 47.0±2 NS NS NS NS
Same work load 123.0±3 106.0±4 105.0±3 100.0±3 <0.001 NS NS NS
I mm time (min)
CMs 3.4±0.4 4.8±0.5 50±0.6 5.5±0.7 <0.001 <0.001 NS NS
CCs 3.7±0.5 5.4±0.6 5.6±0.7 6.1 ±0.8 <0.001 <0.001 NS <0.05
2 mm time (rmn)
CMs 5.1 ±0.7 7.3±0.8 7.4±0.8 8.3 ± 1.0 <0.001 <0.001 NS <0.01
CCs 5.2±0.7 7.5±0.8 7.5±0.8 8.6±0.9 <0.001 <0.001 NS <0.001
MST (mm)
CMs 1.9±0.1 2.1 ±O.I 1.9±0.1 2.2±0.2 NS NS NS <0.05
CCs 1.8±0.2 1.8±0.1 1.9±0.1 2.5 ±0.3 NS NS NS NS
MST/ex. time (mm/min)
CMs 0.48 ± 0.06 0.33±0.06 0.33±0.05 0.30±0.05 <0.01 <0.01 NS NS
CCs 0.42 ± 0.06 0.3±0.05 0.30±0.05 0.29±0.05 <0.05 <0.05 NS NS
ST recovery (mm)
CMs 1.5 ±0.2 1.5±0.1 1.6±0.1 1.6±0.1 NS NS NS NS
CCs 1.4±0.2 1.3±0.1 1.3±0.1 1.5±0.2 NS NS NS NS
Rate-pressure product 154.0±6 156.0±7 157.0±6 156.0±8 NS NS NS NS
(peak unit)
ST same ex. time (mm)
CM s 1.9±0.1 1.3±0.2 1.2 ± 0.2 1.0± 0.2 <0.001 <0.001 NS <0.05
CCs 1.8±0.2 1.1±0.2 1.I ±0.2 0.9±0.2 <0.001 <0.001 NS <0.05
I mm time = time taken for developing I mm ST depression relative to resnng level. 2 mm time = time taken for developing 2 mm ST depression relative to resung
level; Ex. time = exercise time in minutes; HR = heart rate/rmnute, MST = maximal ST depression (mm). NS = not sigrnficant: p = probabihty valve: pI = P value
between placeboand 180 mg/dayof dilnazern; p2 = P value between placeboand 360 rug/day. p3 = P valuebetween 180and 270 rng/day: p4 = P value between 180and
360 mg/day
All values are mean ± standard error of mean All ST segment values are In rnm, all heart rate valuesare In beats per minute. all timed vanables are In minutes and
rate-pressure product is the product of systolic blood pressure and heart rate divided by 100uruts
The exercise data of a patient during placebo and diltiazem
therapy are shown in Figures 8 and 9.
Twenty-four hour ambulatory monitoring. No patient
showed prolongation of the PR interval or higher degrees
of heart block. All the dose levels of diltiazem produced a
moderate reduction of ambulatory heart rate that was sig-
nificantly less than that with placebo (Fig. 9). There was
no significant difference among the various dose levels. The
mean number of minutes in which the ST segment was
depressed more than I mm in lead eMs was 74 ± 23 during
placebo adminitration. This was significantly reduced to
22 ± 5 minutes during treatment with 120 mg three times
a day of diltiazem (p < 0.05). The total area of ST segment
depression in 24 hours was 127 ± 40 units on placebo and
this was reduced to 63 ± 20 units on diltiazem (p < 0.05).
The maximal depth of ST segment depression was 2.2 mm
on placebo and this was not significantly altered by dilti-
azem. The number of minutes in 24 hours during which the
mean heart rate exceeded 100 beatslmin was 95 ± 30 on
placebo but only 33 ± 15 minutes on diltiazem (p < 0.05).
Left ventricular function. No significant changes in
any of the measured variables were observed with any of
the dose levels of diltiazem.
Plasma drug levels. The mean plasma levels during 60
mg three times a day di1tiazem therapy ranged from 58 to
236 nglml (mean 118 ± 15). This increased to 172 ± 26
ng/ml (range 74 to 333) with the 90 mg three times a day
dose and 256 ± 24 nglml (range 102 to 434) on the 120
mg three times a day dose.
Side effects. One patient was withdrawn from the study
because of the occurrence of ankle edema during the treat-
ment with 120 mg three times a day. This patient had tol-
erated the lower doses without any side effects. One patient
complained of swelling and stiffness of the fingers and three
patients complained of shoulder and elbow pain on the 120
mg three times a day dose. These complaints were not severe
enough to require treatment or withdrawal of the drug. Gen-
erally the drug was very well tolerated with minimal side
effects.
Biochemical profile. Three patients showed an increase
in serum creatine kinase values above the normal range.
One patient had a placebo level of 266 IUlliter and this
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Figure 8. Continuous ST and heart rate plots of
the same patient (68 year old man) during pla-
cebo and diltiazem treatment. Time is on the
horizontal axis with 2 minute intervals marked.
ST level is on the vertical axis with lines at I
mm intervals marked. The end of exercise is
denoted by a vertical line in the middle of each
panel. The improvement in exercise tolerance
and ST depression is clearly evident.
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increased to 402 IU/liter at the 120 mg three times a day
diltiazem dose level. The other two had values of 308 and
182 IU/liter, respectively, at this dose compared with pla-
cebo levels of 115 and 121 IUlliter. There was no concom-
itant increase in other enzyme levels. The mean creatine
kinase levels for the group were not significantly altered by
therapy.
Discussion
There have been important advances in therapy aimed at
preventing anginal attacks over the last 20 years. Beta-
adrenergic blocking agents have become widely used and
produce symptomatic and objective improvement in more
than 50% of patients with chronic stable angina (20-22).
Calcium channel blocking agents have been widely used for
vasospastic angina and have been found useful in chronic
stable angina (23). We carried out controlled trials with
verapamil and reported excellent symptomatic and objective
improvement with this calcium antagonist (7,8). However,
our experience has shown that there is a group of patients
who either cannot tolerate these drugs or do not obtain
adequate relief despite high dosage. These patients would
normally be considered for coronary artery bypass surgery
for relief of symptoms. The availability of another effective
drug could offer a useful alternative therapy for these pa-
tients to either delay or obviate the need for surgery.
Antianginal effects of diltiazem. Diltiazem greatly im-
proved the exercise tolerance of the patients and there was
a dose-dependent increase in the number of patients rendered
angina-free (eight with the highest dose level). There was
a dose-dependent increase in the mean exercise time and
improvement in other objective variables. The smallest dose
was moderately effective and the best effect was seen with
120 mg three times a day. Unlike findings with beta-adren-
ergic receptor blocking agents, increasing dose was not as-
sociated with increasing bradycardia at rest, and the initial
heart rate reduction of 11 beats/min was maintained. Side
effects were minimal. It is possible that the lower dose may
be adequate in patients with milder angina and higher doses
may be tried in patients with more severe pain; other workers
(3-6) have reported that diltiazem is effective at doses lower
than those found effective in our patients, who had relatively
severe and resistant angina.
Other effects of diltiazem: comparison with vera-
pamil. The pharmacologic action of diltiazem appears sim-
ilar to that of verapamil (24). The preparation used in this
trial was a controlled-release formulation with a half-life of
about 5 hours. The heart rate at rest was moderately reduced
but the maximal heart rate and peak rate-pressure product
were unchanged. Similarly, the ST segment depression at
maximal exercise was unaltered. However, there was a marked
attenuation of heart rate gain during exercise. We noted
similar effects with verapamil (7,8). The main difference
from diltiazem was the absence of constipation as a side
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Figure 9. Mean hourly heart rates during 24
hour ambulatory electrocardiography monitor-
ing in 21 patients during treatment with placebo
and with diltiazern, 60, 90 and 120 mg three
times a day.
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effect and improvement in exercise tolerance in patients
already resistant to verapamil. Clinically, we have seen
patients resistant to diltiazem responding to verapamil, and
the availability of both drugs should expand the physician's
choice for treating chronic stable angina. The only bio-
chemical abnormality observed was an increase in serum
creatine kinase levels in three patients who had elevated
levels initially. The serum creatine kinase level should be
monitored in patients needing the highest dose level if they
show an already elevated level before treatment.
The protocol used in this study has been reported pre-
viously (7,8). It was designed to eliminate observer bias
and subjective variations and yield a number of comput-
erized objective variables to give a clear pharmacologic
action profile of the drug. We have investigated several
antianginal drugs using an identical protocol and the efficacy
of diltiazem compares favorably with that of verapamil (22).
The reproducibility of exercise time in this group was sat-
isfactory. The untreated mean exercise time was 5.3 ± 0.6
minutes and the placebo value was 5.5 ± 0.7 minutes (p
= not significant).
The ambulatory monitoring data confirmed the findings
on exercise testing. The maximal depth of ST segment
depression was not altered but the duration and area of ST
segment depression during 24 hours were reduced. The heart
rate was reduced at all dose levels and there was no sig-
nificant difference among the various dose levels.
Left ventricular function as estimated by 100 beat-av-
eraged systolic time intervals showed no change with dil-
tiazem therapy. This was our experience with other calcium
antagonists.
In conclusion, diltiazem is a calcium channel blocker
with a powerful antianginal action and minimal side effects.
It is effective in patients resistant to other antianginal agents
and merits a place among the first line antianginal drugs.
The technical assistance of Brenda Christacopoulos, Jayshree Sarma and
the secretarial help of Jean Wright are acknowledged.
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